

CURRICULUM VITAE – PAWEL NAMSOLLECK

- 2015 – 2022 Lanthio Pharma
Groningen
The Netherlands
- Head of Non-Clinical Development, pharmacologist, member of Management Board
- Project management, planning, outsourcing and analysing toxicology/safety pharmacology and efficacy studies of lanthi-peptides for oncology, cardiovascular and respiratory indications
 - Writing and reviewing business and development plans, Investigator Brochures (IB), SOPs, study reports. Preparation of patent applications. Pharmacokinetic and pharmacodynamic data analysis
 - Management of scientific team, consultants, and key-opinion leaders
 - Co-planning and co-management of Phase I clinical trial
 - Management of company website and data storage system
 - Comprehensive presentation of development programs to investors and at scientific congresses
 - Business Development-related activities: identifying potential investors, analysis of market potential and competitive landscape, risk assessment, writing of drug portfolios, discussion with pharma industry and investors
 - Pre-clinical statistical data analysis in GraphPad Prism. Predictive models (regression and machine learning) in pre-clinical development and biomarker discovery/validation in KNIME. Data visualization in Power BI
- 2015 Dissertation at Charité – Universitätsmedizin Berlin (PhD in Pharmacology):
- Pharmacological stimulation of the AT2 receptor activates endogenous neuro- protective and neuro-regenerative mechanisms via BDNF-mediated signaling
- 2012 – 2015 CARIM School for Cardiovascular Diseases
Maastricht University
The Netherlands
- Scientific co-worker
- Working within the projects: “Development of *in vitro* blood-brain barrier models”, “Renin-angiotensin system in small-vessel disease”, “Renin-angiotensin system in blood-brain barrier integrity”
- Conceptualising and carrying out of the PhD student course “Drug Development”

- 2006 – 2012 CCR, Center for Cardiovascular Research
Charité – Universitätsmedizin Berlin
Institute of Pharmacology
Germany
Scientific co-worker
- Executive lead in non-clinical development of non-peptidic AT2 receptor agonist Compound 21 (planning and carrying out efficacy studies, supervision PhD students involved in the C21 development program)
 - Working within projects: “Antibiotics for stroke treatment”, “Stroke-induced colitis”, “AT2 receptor stimulation in spinal cord injury”, „AT2 receptor stimulation in animal model of MS” and „Molecular interactions between AT2- and Mas-receptor”
 - Teaching of medical students within the course: “General Pharmacology and Toxicology”
- Conceptualising and carrying out of the PhD student seminar “Young CCR”, leader of the microscopy lab, supervision of diploma students and trainees, public relations
- 2000 – 2006 German Institute for Human Nutrition (DIfE) Potsdam-Rehbrücke
Dept. of Gastrointestinal Microbiology
Germany
Scientific co-worker
- Work within the scope of the EU project Microbe Diagnostics: Development and validation of novel, culture-independent methods for analysing of microbial communities”
 - Conceptualising and carrying out of the projects in cooperation with:
FU Berlin, Benjamin Franklin Clinic, Dept of Gastroenterology; FU Berlin, Dept of Pharmaceutical Technology; University Hospital Schleswig-Holstein, Campus Kiel, Clinic for General Internal Medicine
- Important responsibilities: leader of the electron microscopy lab, public relations (reports, presentations, publications, posters), supervision of diploma students and trainees
- 1994 – 2000 University of Gdansk, Institute of Oceanography, Dept of Marine Biology Graduation as Master of Science

CERTIFICATES

Good Clinical Praxis (GCP); Service Provider, Contractor Selection and Management; Preparation and Management of SOPs; US Regulatory Strategy for Biologics and Pharmaceutical Drugs; Machine Learning in Healthcare; Data Science and Data Preparation in KNIME

LANGUAGES

Polish	Native speaker
English	Fluent
German	Fluent
Dutch	Intermediate level